Heart failure is a growing health and economic burden in ageing populations. Symptoms are often non-specific and do not help to discriminate between HF and other problems. Both B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) assist in making the diagnosis of HF and in determining its prognosis. In this webinar, you will learn the IFCC recommendations on the appropriate use, analytical performance, and gaps in clinical studies related to the use of natriuretic peptide (NP) assays.
Topics:
Appropriate use, analytical performance of Natriuretic Peptides assays
Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure
Why should you attend
Learning from sharing on the appropriate use, analytical performance, and gaps in clinical studies related to the use of natriuretic peptide (NP) assays
Learning from Clinician perspective on underlying biology of NP production and clearance in health and disease, as well as analytic issues that influence their clinical application, especially with regard to heart failure (HF)
Participate in Live Q&A session
Agenda:
Faculty:
Facilitator / Speaker
Prof. Peter Kavsak
PhD, FCACB, FAACC, FCCS
Professor
Department of Pathology and Molecular Medicine, McMaster University, Canada
Dr. Kavsak is a Professor in the Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario, Canada. He is also a Fellow of the Canadian Academy of Clinical Biochemistry, the American Association for Clinical Chemistry (AACC) Academy, and the Canadian Cardiovascular Society. He provides service as a clinical chemist within the Hamilton Regional Laboratory Medicine Program and is primarily based at the Juravinski Hospital and Cancer Centre with special clinical and academic focus and interests in the cardiac and cancer related laboratory tests. Previously, he was Editor-in-Chief for Clinical Biochemistry (2012-2017) and currently is an Editorial Board member on 6 different scientific journals, most notably Clinical Chemistry, Canadian Journal of Cardiology, and Clinical Chemistry and Laboratory Medicine. He has over 200 publications, with approximately 70% in the cardiac field. He is currently a member (2nd term) on the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB).
[/read]
Speaker
Prof. Carolyn Lam
MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Senior Consultant
National Heart Centre, Singapore
Professor Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.
She started the first Heart Failure with Preserved Ejection Fraction Program and Women’s Heart Health Clinic in Singapore. She is the Program Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study), a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study), as well as a multinational Asian registry of diabetes (Asian Diabetes Outcomes Registry [ADORE]) in collaboration with the American College of Cardiology’s Diabetes Collaborative Registry.
She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and European Journal of Heart Failure.
She is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of the health programme “Body and Soul” by MediaCorp Singapore
[/read]
